Coeptis Therapeutics Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0396
- Today's High:
- $0.04
- Open Price:
- $0.0396
- 52W Low:
- $0.0344
- 52W High:
- $0.2
- Prev. Close:
- $0.0362
- Volume:
- 1205
Company Statistics
- Market Cap.:
- $0
- Book Value:
- 0.156
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -224.42%
- Return on Equity TTM:
- -1024.34%
Company Profile
Coeptis Therapeutics Holdings Inc had its IPO on 2020-12-17 under the ticker symbol COEPW.
The company operates in the Healthcare sector and Biotechnology industry. Coeptis Therapeutics Holdings Inc has a staff strength of 4 employees.
Stock update
Shares of Coeptis Therapeutics Holdings Inc opened at $0.04 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.04 - $0.04, and closed at $0.04.
This is a +10.5% increase from the previous day's closing price.
A total volume of 1,205 shares were traded at the close of the day’s session.
In the last one week, shares of Coeptis Therapeutics Holdings Inc have increased by +60%.
Coeptis Therapeutics Holdings Inc's Key Ratios
Coeptis Therapeutics Holdings Inc has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Coeptis Therapeutics Holdings Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32819660. The EBITDA ratio measures Coeptis Therapeutics Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Coeptis Therapeutics Holdings Inc’s operating margin was 0% while its return on assets stood at -224.42% with a return of equity of -1024.34%.
In Q1, Coeptis Therapeutics Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Coeptis Therapeutics Holdings Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Coeptis Therapeutics Holdings Inc’s profitability.
Coeptis Therapeutics Holdings Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Coeptis Therapeutics Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.94 million
- Total Liabilities
- $1.98 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Coeptis Therapeutics Holdings Inc ended 2024 with $5.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.94 million while shareholder equity stood at $1.29 million.
Coeptis Therapeutics Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $1.98 million in other current liabilities, 2094.00 in common stock, $-73607967.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.11 million and cash and short-term investments were $2.11 million. The company’s total short-term debt was $1,531,561 while long-term debt stood at $150000.00.
Coeptis Therapeutics Holdings Inc’s total current assets stands at $2.28 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $242453.00 and inventory worth $0.
In 2024, Coeptis Therapeutics Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Coeptis Therapeutics Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.04
- 52-Week High
- $0.2
- 52-Week Low
- $0.0344
- Analyst Target Price
- $
Coeptis Therapeutics Holdings Inc stock is currently trading at $0.04 per share. It touched a 52-week high of $0.2 and a 52-week low of $0.2. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.06 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Coeptis Therapeutics Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn’s disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.